MINDCURE News

March 16, 2022

MINDCURE Provides Update on Strategic Review

March 2, 2022

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

February 10, 2022

MINDCURE Announces Strategic Review

February 3, 2022

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

January 25, 2022

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

January 6, 2022

MINDCURE to Participate in the H.C. Wainwright Bioconnect Conference in January 2022

December 16, 2021

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

December 14, 2021

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

December 3, 2021

MINDCURE to Participate in Upcoming Conferences in December 2021

November 4, 2021

MINDCURE Provides Update on Studies and Clinical Trials

October 28, 2021

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

October 27, 2021

MINDCURE Announces Participation at Upcoming Events in November 2021

October 26, 2021

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

October 7, 2021

MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021

September 30, 2021

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

September 28, 2021

MINDCURE to Present at the Benzinga Healthcare Small Cap Conference

September 27, 2021

MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

September 23, 2021

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

September 22, 2021

MINDCURE Announces Inclusion in AdvisorShares Psychedelics ETF

September 17, 2021

MINDCURE to Participate in Maxim Group LLC's Advances in Mental Health Virtual Conference

September 16, 2021

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

September 9, 2021

MINDCURE Announces Platinum Sponsorship of the 2021 SANA Symposium

September 8, 2021

MINDCURE to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

August 31, 2021

MINDCURE Announces Financial Results for Fiscal 2021

August 26, 2021

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America

August 10, 2021

MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team

August 4, 2021

MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor

July 27, 2021

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

July 13, 2021

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

July 12, 2021

MINDCURE Adopts Advance Notice Policy

June 30, 2021

Maxim Group Initiates Coverage of Mind Cure Health

June 17, 2021

MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression

June 3, 2021

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

May 20, 2021

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

May 19, 2021

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor

April 29, 2021

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth

April 27, 2021

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM

April 22, 2021

MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors

April 21, 2021

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

April 14, 2021

MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment

April 13, 2021

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform

April 8, 2021

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

March 31, 2021

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients

March 22, 2021

Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors

March 19, 2021

Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology

March 15, 2021

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

March 9, 2021

MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study

March 4, 2021

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

March 3, 2021

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research

March 2, 2021

MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin

February 18, 2021

MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform

February 17, 2021

Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics

February 17, 2021

Mind Cure Comments on Recent Promotional Activity

February 16, 2021

MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization

February 11, 2021

MINDCURE Announces Listing of Warrants

February 10, 2021

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

January 26, 2021

MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category

January 22, 2021

Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering

January 21, 2021

MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index

January 12, 2021

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

January 6, 2021

Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research

December 31, 2020

Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club

December 29, 2020

Mind Cure Announces Novel Supplement Product to Address Teen Wellness

Mind Cure Announces Closing of Oversubscribed $3.6 Million Offering

Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer

Mind Cure Announces Eligibility for DTC Trading